Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.
暂无分享,去创建一个
Z. Wang | B. Kong | Jing Xu | Lei Zhang | Zhiwei Wang | Pu Chen | Zhipeng Cao | Minglu Hao | J. Xin | Biao Kong | Jing Xu
[1] J. Tabernero,et al. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study , 2021, ESMO open.
[2] T. Kondo,et al. Integrative analyses of gene expression and chemosensitivity of patient-derived ovarian cancer spheroids link G6PD-driven redox metabolism to cisplatin chemoresistance. , 2021, Cancer letters.
[3] John F. Ouyang,et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology , 2021, Nature Communications.
[4] H. Nagano,et al. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[5] Nancy T. Li,et al. An Engineered Patient‐Derived Tumor Organoid Model That Can Be Disassembled to Study Cellular Responses in a Graded 3D Microenvironment , 2021, Advanced Functional Materials.
[6] K. Chatterjee,et al. 3D Tumor Models for Breast Cancer: Whither We Are and What We Need. , 2021, ACS biomaterials science & engineering.
[7] Y. Cho,et al. Establishment of patient‐derived organotypic tumor spheroid models for tumor microenvironment modeling , 2021, Cancer medicine.
[8] Ji Hun Yang,et al. Drug screening by uniform patient derived colorectal cancer hydro-organoids. , 2021, Biomaterials.
[9] D. Witonsky,et al. Genomic and epigenomic active vitamin Dresponses in human colonic organoids. , 2021, Physiological genomics.
[10] Shaohua Ma,et al. Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids , 2021, Cancer biology & medicine.
[11] E. Oki,et al. Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. , 2021, Clinical colorectal cancer.
[12] Yoav Mayshar,et al. Heterozygous APC germline mutations impart predisposition to colorectal cancer , 2021, Scientific Reports.
[13] S. Batra,et al. Recent advances in organoid development and applications in disease modeling. , 2021, Biochimica et biophysica acta. Reviews on cancer.
[14] A. Hsieh,et al. A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture , 2021, Scientific Reports.
[15] Q. Cheng,et al. A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening. , 2020, Cancer letters.
[16] A. Atala,et al. 3-D Human Renal Tubular Organoids Generated from Urine-Derived Stem Cells for Nephrotoxicity Screening , 2020, ACS biomaterials science & engineering.
[17] G. van der Pluijm,et al. Patient-derived tumour models for personalized therapeutics in urological cancers , 2020, Nature Reviews Urology.
[18] J. An,et al. Lactobacillus-derived metabolites enhance the antitumor activity of 5-FU and inhibit metastatic behavior in 5-FU-resistant colorectal cancer cells by regulating claudin-1 expression , 2020, Journal of Microbiology.
[19] Jun Yu,et al. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. , 2020, Gastroenterology.
[20] L. del Peso,et al. Comparative Study of Organoids from Patient-Derived Normal and Tumor Colon and Rectal Tissue , 2020, Cancers.
[21] M. Rubin,et al. Patient-derived xenografts and organoids model therapy response in prostate cancer , 2020, Nature Communications.
[22] Junjie Peng,et al. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. , 2019, Cell stem cell.
[23] L. Miller,et al. Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling and Chemotherapy Screening. , 2019, ACS biomaterials science & engineering.
[24] A. Oudenaarden,et al. Long‐term expanding human airway organoids for disease modeling , 2019, The EMBO journal.
[25] F. Di Palma,et al. Integrative analysis of Paneth cell proteomic and transcriptomic data from intestinal organoids reveals functional processes dependent on autophagy , 2019, Disease Models & Mechanisms.
[26] Jijun Cheng,et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response , 2018, Cancer communications.
[27] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[28] G. Risbridger,et al. Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models. , 2018, Cold Spring Harbor perspectives in medicine.
[29] Wei Chen,et al. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients , 2018, Cancer communications.
[30] Andrea Sottoriva,et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.
[31] Hans Clevers,et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity , 2018, Cell.
[32] M. Reagan,et al. 3d Tissue Engineered In Vitro Models Of Cancer In Bone. , 2017, ACS biomaterials science & engineering.
[33] B. Shi,et al. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells , 2017, Protein & Cell.
[34] Rameen Beroukhim,et al. Patient-derived xenografts undergo murine-specific tumor evolution , 2017, Nature Genetics.
[35] B. Chabner,et al. NCI-60 Cell Line Screening: A Radical Departure in its Time. , 2016, Journal of the National Cancer Institute.
[36] Joshua M. Korn,et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.
[37] Bon-Kyoung Koo,et al. Modeling mouse and human development using organoid cultures , 2015, Development.
[38] J. Maris,et al. Improving Patient Outcomes With Cancer Genomics: Unique Opportunities and Challenges in Pediatric Oncology. , 2015, JAMA.
[39] Ash A. Alizadeh,et al. Toward understanding and exploiting tumor heterogeneity , 2015, Nature Medicine.
[40] Hayley E. Francies,et al. Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.
[41] Liewei Wang,et al. In vitro human cell line models to predict clinical response to anticancer drugs. , 2015, Pharmacogenomics.
[42] M. Spector,et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.
[43] Zachary C. Dobbin,et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer , 2014, Oncotarget.
[44] Juergen A. Knoblich,et al. Organogenesis in a dish: Modeling development and disease using organoid technologies , 2014, Science.
[45] Jason R Spence,et al. How to make an intestine , 2014, Development.
[46] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[47] H. Clevers,et al. Growing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications , 2013, Science.
[48] Hans Clevers,et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.
[49] Hans Clevers,et al. Isolation and in vitro expansion of human colonic stem cells , 2011, Nature Medicine.
[50] K. Polyak,et al. Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.
[51] H. Clevers,et al. Single Lgr5 stem cells build cryptvillus structures in vitro without a mesenchymal niche , 2009, Nature.
[52] C. Köhne,et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial , 2007 .
[53] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[54] M. Komatsu,et al. Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test , 2005, Anti-cancer drugs.
[55] I. Fichtner,et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. , 2004, European journal of cancer.
[56] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.